KalVista Pharmaceuticals Ownership | Who Owns KalVista Pharmaceuticals?
KalVista Pharmaceuticals Ownership Summary
KalVista Pharmaceuticals is owned by 46.19% institutional investors, 1.65% insiders, and 52.16% retail investors. Vr adviser is the largest institutional shareholder, holding 12.81% of KALV shares. American Funds SMALLCAP World A is the top mutual fund, with 5.48% of its assets in KalVista Pharmaceuticals shares.
KALV Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | KalVista Pharmaceuticals | 46.19% | 1.65% | 52.16% |
| Sector | Healthcare Stocks | 35.58% | 11.87% | 52.55% |
| Industry | Biotech Stocks | 35.75% | 11.83% | 52.41% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vr adviser | 6.47M | 12.81% | $130.33M |
| Frazier life sciences management | 4.96M | 9.82% | $99.87M |
| Suvretta capital management | 4.77M | 9.44% | $95.99M |
| Tang capital management | 4.57M | 9.05% | $92.07M |
| Blackrock funding, inc. /de | 3.80M | 7.51% | $76.41M |
| Blackrock | 2.95M | 6.76% | $34.69M |
| Silverarc capital management | 2.88M | 5.69% | $57.90M |
| Capital world investors | 2.81M | 5.56% | $56.54M |
| Vanguard group | 2.51M | 4.66% | $40.52M |
| Point72 asset management | 2.14M | 4.23% | $43.02M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Silverarc capital management | 2.88M | 5.91% | $57.90M |
| Allostery investments lp | 40.00K | 5.76% | $452.20K |
| Vr adviser | 6.47M | 4.86% | $130.33M |
| Tang capital management | 4.57M | 4.68% | $92.07M |
| Parkman healthcare partners | 1.84M | 3.81% | $36.95M |
| Octagon capital advisors lp | 1.45M | 3.23% | $29.19M |
| Great point partners | 675.00K | 3.12% | $13.59M |
| Frazier life sciences management | 4.96M | 2.57% | $99.87M |
| Suvretta capital management | 4.77M | 2.45% | $95.99M |
| Kynam capital management, lp | 1.82M | 2.26% | $36.66M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Tudor investment corp et al | 2.00M | 0.00% | 2.00M |
| Sio capital management | 683.82K | 2.11% | 683.82K |
| Driehaus capital management | 564.04K | 0.08% | 564.04K |
| Blackrock | 2.95M | 0.00% | 512.88K |
| Silverarc capital management | 2.88M | 5.91% | 449.29K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Tcg crossover management | - | - | -1.16M |
| Millennium management | 1.91M | 0.02% | -984.52K |
| Bioimpact capital | - | - | -896.91K |
| Schroder investment management group | 506.74K | 0.01% | -665.01K |
| Perceptive advisors | - | - | -500.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Tudor investment corp et al | 2.00M | 0.00% | 2.00M | $2.18M |
| Sio capital management | 683.82K | 2.11% | 683.82K | $8.33M |
| Driehaus capital management | 564.04K | 0.08% | 564.04K | $11.35M |
| Catalio capital management, lp | 426.55K | 1.79% | 426.55K | $8.59M |
| Vanguard fiduciary trust | 276.39K | 0.00% | 276.39K | $5.56M |
Sold Out
| Holder | Change |
|---|---|
| National bank of canada /fi/ | -1.00 |
| Ifp advisors | -5.00 |
| Nelson, van denburg & campbell wealth management group | -5.00 |
| Creekmur asset management | -23.00 |
| Corecap advisors | -23.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 122 | -25.61% | 23,341,990 | -65.14% | 46 | 0.30% | 66 | -27.47% | 28 | -41.67% |
| Dec 31, 2025 | 128 | -15.79% | 45,617,570 | -22.20% | 84 | 0.70% | 72 | -7.69% | 37 | -5.13% |
| Sep 30, 2025 | 148 | 1.37% | 60,631,934 | 11.36% | 113 | 0.94% | 75 | -7.41% | 39 | 11.43% |
| Jun 30, 2025 | 145 | 5.07% | 54,415,240 | -0.92% | 109 | 1.01% | 80 | 12.68% | 35 | -7.89% |
| Mar 31, 2025 | 138 | 5.34% | 54,920,723 | -0.49% | 104 | 0.75% | 71 | -7.79% | 38 | 26.67% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| American Funds SMALLCAP World A | 2.81M | 5.48% | - |
| Vanguard Total Stock Mkt Idx Inv | 1.35M | 2.54% | - |
| Vanguard US Total Market Shares ETF | 1.20M | 2.41% | - |
| APO Medical Opportunities R | 1.17M | 2.31% | 866.80K |
| State Street® SPDR® S&P® Biotech ETF | 1.20M | 2.26% | -11.88K |
| MEDICAL BioHealth EUR Acc | 977.93K | 1.84% | -1.00K |
| iShares Russell 2000 ETF | 905.84K | 1.70% | 7.61K |
| International Biotechnology Ord | 746.05K | 1.47% | -425.70K |
| apo Medical Opportunities R | 774.91K | 1.46% | 36.00K |
| SPDR® S&P Biotech ETF | 571.42K | 1.13% | 1.27K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| May 27, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | $905.22K |
| May 26, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | $52.65K |
| May 26, 2026 | Sweeny Nicole | Chief Commercial Officer | Sell | $39.87K |
| May 26, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | $59.96K |
| May 22, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | $292.65K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | 17 |
| 2026 Q1 | - | 15 |
| 2025 Q4 | - | 10 |
| 2025 Q3 | - | 13 |
| 2025 Q2 | 1 | 9 |
KALV Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools